Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Jérémie Roux"'
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Single-cell multimodal technologies reveal the scales of cellular heterogeneity impairing cancer treatment, yet cell response dynamics remain largely underused to decipher the mechanisms of drug resistance they take part in. As the phenotypi
Externí odkaz:
https://doaj.org/article/9fa5a24dec424b0e9ffb9978e6e36deb
Autor:
Benjamin Bian, Agnès Paquet, Marie-Jeanne Arguel, Mickael Meyer, Ludovic Peyre, Asma Chalabi, Marielle Péré, Kevin Lebrigand, Rainer Waldmann, Pascal Barbry, Paul Hofman, Jérémie Roux
Publikováno v:
STAR Protocols, Vol 3, Iss 3, Pp 101600- (2022)
Summary: Cell response variability is a starting point in cancer drug resistance that has been difficult to analyze because the tolerant cell states are short lived. Here, we present fate-seq, an approach to isolate single cells in their transient st
Externí odkaz:
https://doaj.org/article/278a66e552af47f4a13fc20d8f42b23a
Autor:
Augusto Sales de Queiroz, Guilherme Sales Santa Cruz, Alain Jean-Marie, Dorian Mazauric, Jérémie Roux, Frédéric Cazals
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0268956 (2022)
Prioritizing genes for their role in drug sensitivity, is an important step in understanding drugs mechanisms of action and discovering new molecular targets for co-treatment. To formalize this problem, we consider two sets of genes X and P respectiv
Externí odkaz:
https://doaj.org/article/8b9205bdc6f44d73b55619f2ed0a463d
Autor:
Yanni Zhu, Nicole Bassoff, Clemens Reinshagen, Deepak Bhere, Michal O. Nowicki, Sean E. Lawler, Jérémie Roux, Khalid Shah
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Developing therapeutics that target multiple receptor signaling pathways in tumors is critical as therapies targeting single specific biomarker/pathway have shown limited efficacy in patients with cancer. In this study, we extensively charac
Externí odkaz:
https://doaj.org/article/2012dc1702134a00bc4fa931d84efa4f
Autor:
Jérémie Roux, Marc Hafner, Samuel Bandara, Joshua J Sims, Hannah Hudson, Diana Chai, Peter K Sorger
Publikováno v:
Molecular Systems Biology, Vol 11, Iss 5, Pp 1-17 (2015)
Abstract When cells are exposed to death ligands such as TRAIL, a fraction undergoes apoptosis and a fraction survives; if surviving cells are re‐exposed to TRAIL, fractional killing is once again observed. Therapeutic antibodies directed against T
Externí odkaz:
https://doaj.org/article/6e360956b93c4ce48e060381bc9b5364
Autor:
Jean-François Pittet, Hidefumi Koh, Xiaohui Fang, Karen Iles, Sarah Christiaans, Naseem Anjun, Brant M Wagener, Dae Won Park, Jaroslaw W Zmijewski, Michael A Matthay, Jérémie Roux
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63907 (2013)
High mobility group box 1 (HMGB1) protein is a danger-signaling molecule, known to activate an inflammatory response via TLR4 and RAGE. HMGB1 can be either actively secreted or passively released from damaged alveolar epithelial cells. Previous studi
Externí odkaz:
https://doaj.org/article/c227c38bbb9c4b919ffa5c4c5dc7d4bf
Autor:
Jean-François Pittet, Hidefumi Koh, Xiaohui Fang, Karen Iles, Sarah Christiaans, Naseem Anjun, Brant M. Wagener, Dae Won Park, Jaroslaw W. Zmijewski, Michael A. Matthay, Jérémie Roux
Publikováno v:
PLoS ONE, Vol 8, Iss 10 (2013)
Externí odkaz:
https://doaj.org/article/cabda09a3884455fb8ad23c9dc08f114
Autor:
Brest, Olivia Vidal-Cruchez, Victoria J. Nicolini, Tifenn Rete, Karine Jacquet, Roger Rezzonico, Caroline Lacoux, Marie-Angela Domdom, Barnabé Roméo, Jérémie Roux, Arnaud Hubstenberger, Bernard Mari, Baharia Mograbi, Paul Hofman, Patrick
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3078
Overactivation of the mitogen-activated protein kinase (MAPK) pathway is a critical driver of many human cancers. However, therapies directly targeting this pathway lead to cancer drug resistance. Resistance has been linked to compensatory RAS overex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::0f021c9abdb0bfba5dc3b8bb83acbfeb
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 2020, ⟨10.1038/s41416-020-01177-w⟩
British Journal of Cancer, Cancer Research UK, 2020, ⟨10.1038/s41416-020-01177-w⟩
British Journal of Cancer, 2020, ⟨10.1038/s41416-020-01177-w⟩
British Journal of Cancer, Cancer Research UK, 2020, ⟨10.1038/s41416-020-01177-w⟩
The continuing efforts to exploit the death receptor agonists, such as the tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), for cancer therapy, have largely been impaired by the anti-apoptotic and pro-survival signalling pathwa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a4243552a76acc92de7a0cb7294b16
https://doi.org/10.1038/s41416-020-01177-w
https://doi.org/10.1038/s41416-020-01177-w
Publikováno v:
Foundations of Systems Biology in Engineering (FOSBE)
Foundations of Systems Biology in Engineering (FOSBE), Aug 2022, Cambridge, Massachusetts, United States
Foundations of Systems Biology in Engineering (FOSBE), Aug 2022, Cambridge, Massachusetts, United States
International audience; Cell response heterogeneity upon drug treatment is a leading cause of reduced drug efficacy in preclinical cancer research. Although single-cell studies have revealed the depth of cellular heterogeneity observed between in tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b55df9a5d8ce5ad52146af47385645
https://hal.science/hal-03868311
https://hal.science/hal-03868311
